US Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucoma

Nicoy announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma. Latanoprostene bunod ophthalmic solution, 0.024%, is commercialized as Vyzulta for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.

Vyzulta is commercialized by Nicox’s exclusive global licensee Bausch + Lomb in the U.S. (since 2017), Canada (2019), Argentina (2020), Mexico (2020) and Hong Kong (2020), and is now approved in 5 other territories (Brazil, Colombia, South Korea, Taiwan and Ukraine).

Under the terms of the exclusive global license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of Vyzulta plus up to $150 million in potential future milestone payments.